Equities analysts expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report sales of $5.33 billion for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Teva Pharmaceutical Industries Limited’s earnings, with estimates ranging from $5.26 billion to $5.40 billion. Teva Pharmaceutical Industries Limited reported sales of $6.49 billion during the same quarter last year, which would suggest a negative year over year growth rate of 17.9%. The firm is expected to report its next quarterly earnings results on Monday, February 12th.

On average, analysts expect that Teva Pharmaceutical Industries Limited will report full-year sales of $5.33 billion for the current fiscal year, with estimates ranging from $22.19 billion to $22.99 billion. For the next year, analysts anticipate that the business will post sales of $20.40 billion per share, with estimates ranging from $19.62 billion to $22.43 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Teva Pharmaceutical Industries Limited.

A number of equities research analysts have weighed in on the stock. Mizuho restated a “neutral” rating and issued a $12.00 price objective (down previously from $15.00) on shares of Teva Pharmaceutical Industries Limited in a report on Friday. Cantor Fitzgerald set a $10.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Tuesday, November 14th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a report on Sunday, November 12th. J P Morgan Chase & Co cut shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underweight” rating and cut their price objective for the stock from $11.48 to $11.00 in a report on Monday, November 13th. Finally, cut shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “reduce” rating in a report on Tuesday, November 7th. Seven equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $21.88.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/11/20/zacks-analysts-anticipate-teva-pharmaceutical-industries-limited-teva-will-post-quarterly-sales-of-5-33-billion.html.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down $0.76 on Monday, reaching $13.08. 16,771,201 shares of the company’s stock were exchanged, compared to its average volume of 15,421,627. The stock has a market capitalization of $12,010.00, a PE ratio of 3.20 and a beta of 0.52. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Limited has a twelve month low of $10.85 and a twelve month high of $39.08.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.085 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.60%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -16.01%.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Security National Bank of Sioux City Iowa IA increased its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after purchasing an additional 87 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after acquiring an additional 94 shares in the last quarter. CIBC Asset Management Inc grew its stake in Teva Pharmaceutical Industries Limited by 0.3% during the second quarter. CIBC Asset Management Inc now owns 65,534 shares of the company’s stock valued at $2,177,000 after acquiring an additional 178 shares in the last quarter. Managed Account Services Inc. grew its stake in Teva Pharmaceutical Industries Limited by 1.4% during the second quarter. Managed Account Services Inc. now owns 14,911 shares of the company’s stock valued at $495,000 after acquiring an additional 211 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC grew its stake in Teva Pharmaceutical Industries Limited by 3.6% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock valued at $279,000 after acquiring an additional 294 shares in the last quarter. 52.29% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries Limited (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.